GSK3196165

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

Arthritis, RheumatoidOsteoarthritis

Phase 2

Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis

CompletedNCT02504671

GlaxoSmithKlineArthritis, Rheumatoid

Start: 2015-07-23End: 2017-12-29Updated: 2021-01-11

A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis

CompletedNCT02683785

GlaxoSmithKlineOsteoarthritis

Start: 2016-03-17End: 2017-11-29Updated: 2021-01-11

Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis

CompletedNCT02799472

GlaxoSmithKlineArthritis, Rheumatoid

Start: 2016-06-15End: 2017-10-30Updated: 2021-01-11

Related Papers

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).

2023-09-1218 citations

Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study.

2020-10-0725 citations

MRI of the joint and evaluation of the granulocyte-macrophage colony-stimulating factor-CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study.

2020-10-0718 citations

Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial.

2020-09-2315 citations